Company news

Edgewise Therapeutics, Inc. news in 2025

Edgewise Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy

December 23, 2025

Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

November 19, 2025

Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers

November 9, 2025

Edgewise Therapeutics to Participate in Upcoming Investor Conferences

November 6, 2025

Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 5, 2025

Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society

October 1, 2025

Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 6, 2025

Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies

June 25, 2025

Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference

June 2, 2025

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025

May 13, 2025

Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025

Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock

April 1, 2025

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)

April 1, 2025

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8: 30 am Eastern Time

March 25, 2025

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference

March 10, 2025

Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025

March 3, 2025

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

March 2, 2025

Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development

January 21, 2025

Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025

January 12, 2025

Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

January 6, 2025

Decks in 2025